EUVIMEDEUVIMED entdecken
Multizentrische StudieRandomisierte kontrollierte StudieVergleichsstudieÄquivalenzstudie

Randomized Trial of Biolimus DCB for In-Stent Restenosis

Robert A Byrne, Joo-Yong Hahn, Peter O'Kane, Manel Sabaté, Ralph Toelg, Samuel Copt, Sean Fitzgerald, Marie-Claude Morice, Jasper Trevelyan, Darren Mylotte, Antonio Fernandez Ortiz, Himanshu Rai und 5 weitere

JACC: Cardiovascular Interventions · 2025-03 · 18 (5) · 654-662

DOI: 10.1016/j.jcin.2024.11.026 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift JACC: Cardiovascular Interventions, 2025-03. Verfasst von Robert A Byrne und 16 weiteren Autor:innen. Beteiligte Einrichtung: Cardiovascular Research Institute Dublin, Mater Private Network, Dublin, Ireland; RCSI University of Medicine and Health Sciences, Dublin, Ireland. E…. Hauptthemen laut MEDLINE: Sirolimus, Coronary Restenosis, Cardiovascular Agents, Paclitaxel. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 21 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: In recent years, drug-coated balloon (DCB) angioplasty has become an established treatment option for the treatment of coronary in-stent restenosis (ISR). OBJECTIVES: The aim of this study was to compare the angiographic and clinical performance of the Biolimus A9-coated balloon (BCB; Biosensors Europe) with that of the paclitaxel-coated balloon (PCB; SeQuent Please, Braun Melsungen). METHODS: REFORM (Prospective, Randomized, Non-Inferiority Trial to Determine the Safety and Efficacy of the Biolimus A9™ Drug Coated Balloon for the Treatment of In-Stent Restenosis: First-in-Man Trial) was a multicenter, assessor-blinded, noninferiority, 2:1 randomized controlled trial comparing the BCB and the PCB for the treatment of coronary ISR. The primary endpoint was in-segment percentage diameter stenosis at 6 months. Secondary endpoints included target lesion failure. The trial was registered prospectively at ClinicalTrials.gov (NCT04079192). RESULTS: A total of 202 patients were randomized at 20 centers in 6 countries, with 135 in the BCB group and 67 in the PCB group. The mean patient age was 68.5 ± 10 years. At 6 months, in-segment percentage diameter stenosis was 43.3% ± 22.9% in the BCB group compared with 31.4% ± 17.7% in the PCB group (95% CI for the difference: 4.9%-18.8%; prespecified noninferiority margin 12%, noninferiority P = 0.48). At 1 year, target lesion failure was observed in 23.7% of patients in the BCB group vs 17.1% in the PCB group (HR: 1.44; 95% CI: 0.72-2.88; P = 0.28). CONCLUSIONS: In patients with ISR, the REFORM study failed to demonstrate noninferiority of the investigational biolimus DCB compared with the standard paclitaxel DCB.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SirolimusCoronary RestenosisCardiovascular AgentsPaclitaxelPercutaneous Coronary InterventionCoated Materials, BiocompatibleAngioplasty, Balloon, CoronaryCardiac CathetersDrug-Eluting StentsStentsCoronary Artery DiseaseHumansMaleFemaleAgedTreatment OutcomeProspective StudiesMiddle AgedTime FactorsEuropeCoronary AngiographyProsthesis DesignRisk Factors

Stichwörter der Autor:innen

drug-coated balloonin-stent restenosispercutaneous coronary interventionrandomized

Substanzen

SirolimusCardiovascular AgentsPaclitaxelumirolimusCoated Materials, Biocompatible

Autor:innen und Institutionen

  • Cardiovascular Research Institute Dublin, Mater Private Network, Dublin, Ireland; RCSI University of Medicine and Health Sciences, Dublin, Ireland. Electronic address: robertabyrne@rcsi.ie.
  • Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
  • Royal Bournemouth Hospital, Bournemouth, United Kingdom.
  • Hospital Clinical de Barcelona, Cardiovascular Institute; Institut d'Investigacions Biomèdiques August Pi i Sunyer, Centro de Investigación Biomédica en Red Enfermedades Cardiovaculares, Barcelona, Spain.
  • Heart Center of Segeberger Kliniken, Bad Segeberg, Germany.
  • Biosensors Europe, Morges, Switzerland.

Zitieren

APA

Byrne, R. A., Hahn, J. Y., O'Kane, P., Sabaté, M., Toelg, R., Copt, S., Fitzgerald, S., Morice, M. C., Trevelyan, J., Mylotte, D., Ortiz, A. F., Rai, H., Durand, R., Wöhrle, J., Kleber, F. X., Stefanini, G., & Alfonso, F. (2025). Randomized Trial of Biolimus DCB for In-Stent Restenosis. JACC: Cardiovascular Interventions, 18(5), 654-662. https://doi.org/10.1016/j.jcin.2024.11.026

Vancouver

Byrne RA, Hahn JY, O'Kane P, Sabaté M, Toelg R, Copt S, et al. Randomized Trial of Biolimus DCB for In-Stent Restenosis. JACC: Cardiovascular Interventions. 2025;18(5):654-662. doi:10.1016/j.jcin.2024.11.026

BibTeX
@article{Byrne2025,
  author = {Byrne, Robert A and Hahn, Joo-Yong and O'Kane, Peter and Sabaté, Manel and Toelg, Ralph and Copt, Samuel and Fitzgerald, Sean and Morice, Marie-Claude and Trevelyan, Jasper and Mylotte, Darren and Ortiz, Antonio Fernandez and Rai, Himanshu and Durand, Rory and Wöhrle, Jochen and Kleber, Franz Xever and Stefanini, Giuilo and Alfonso, Fernando},
  title = {Randomized Trial of Biolimus DCB for In-Stent Restenosis},
  journal = {JACC: Cardiovascular Interventions},
  year = {2025},
  volume = {18},
  number = {5},
  pages = {654--662},
  doi = {10.1016/j.jcin.2024.11.026}
}
Kostenlos starten →